KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (KALV)
CUSIP: 483497103
Q4 2025 13F Holders as of 31 Dec 2025
- Type / Class
- Equity / Common Stock, par value $0.001 per share
- Shares outstanding
- 50,580,036
- Total 13F shares
- 66,955,502
- Share change
- +6,300,347
- Total reported value
- $1,081,342,589
- Put/Call ratio
- 14%
- Price per share
- $16.15
- Number of holders
- 161
- Value change
- +$110,817,400
- Number of buys
- 86
- Number of sells
- 66
Quarterly Holders Quick Answers
What is CUSIP 483497103?
CUSIP 483497103 identifies KALV - KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 483497103:
Top shareholders of KALV - KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| VR Adviser, LLC |
13F
|
Company |
13%
|
6,728,985
|
$81,959,037 | — | 30 Sep 2025 | |
| TANG CAPITAL MANAGEMENT LLC |
13D/G
13F
|
Company |
9.9%
|
4,941,798
|
$63,650,358 | $0 | 31 Mar 2025 | |
| Frazier Life Sciences Management, L.P. |
13F
|
Company |
10%
|
5,039,867
|
$61,385,580 | — | 30 Sep 2025 | |
| SUVRETTA CAPITAL MANAGEMENT, LLC |
13F
|
Company |
9.4%
|
4,768,712
|
$58,082,912 | — | 30 Sep 2025 | |
| Frazier Life Sciences Public Fund, L.P. |
13D/G
|
— |
6.9%
|
3,466,521
|
$42,222,226 | +$12,986,864 | 01 Nov 2025 | |
| Capital World Investors |
13D/G
13F
|
Company |
6.4%
|
3,177,587
|
$40,927,321 | $0 | 31 Mar 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13D/G
13F
|
Company |
5.9%
|
2,963,699
|
$39,595,019 | +$5,780,725 | 23 Dec 2025 | |
| BlackRock, Inc. |
13F
|
Company |
6.2%
|
3,126,117
|
$38,076,105 | — | 30 Sep 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
4.9%
|
2,501,119
|
$30,463,629 | — | 30 Sep 2025 | |
| Woodline Partners LP |
13F
|
Company |
3.8%
|
1,920,664
|
$23,393,688 | — | 30 Sep 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
3.6%
|
1,800,181
|
$21,926,205 | — | 30 Sep 2025 | |
| Parkman Healthcare Partners LLC |
13F
|
Company |
3.4%
|
1,735,003
|
$21,132,337 | — | 30 Sep 2025 | |
| STATE STREET CORP |
13F
|
Company |
3.1%
|
1,575,496
|
$19,189,541 | — | 30 Sep 2025 | |
| SILVERARC CAPITAL MANAGEMENT, LLC |
13F
|
Company |
2.7%
|
1,363,378
|
$16,605,944 | — | 30 Sep 2025 | |
| EMERALD ADVISERS, LLC |
13F
|
Company |
2.7%
|
1,351,254
|
$16,458,274 | — | 30 Sep 2025 | |
| Octagon Capital Advisors LP |
13F
|
Company |
2.5%
|
1,273,333
|
$15,509,196 | — | 30 Sep 2025 | |
| SCHRODER INVESTMENT MANAGEMENT GROUP |
13F
|
Company |
2.3%
|
1,158,457
|
$14,144,760 | — | 30 Sep 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.8%
|
928,671
|
$11,313,517 | — | 30 Sep 2025 | |
| EMERALD MUTUAL FUND ADVISERS TRUST |
13F
|
Company |
1.8%
|
917,975
|
$11,180,936 | — | 30 Sep 2025 | |
| Vestal Point Capital, LP |
13D/G
13F
|
Company |
1.5%
|
750,000
|
$9,135,000 | $0 | 30 Sep 2025 | |
| Freestone Grove Partners LP |
13F
|
Company |
1.4%
|
704,448
|
$8,580,177 | — | 30 Sep 2025 | |
| Sio Capital Management, LLC |
13F
|
Company |
1.4%
|
683,819
|
$8,328,915 | — | 30 Sep 2025 | |
| Kynam Capital Management, LP |
13F
|
Company |
1.2%
|
606,171
|
$7,383,163 | — | 30 Sep 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
1.2%
|
596,474
|
$7,265,054 | — | 30 Sep 2025 | |
| BARCLAYS PLC |
13F
|
Company |
1.1%
|
577,904
|
$7,038,871 | — | 30 Sep 2025 | |
| MORGAN STANLEY |
13F
|
Company |
1.1%
|
564,856
|
$6,879,958 | — | 30 Sep 2025 | |
| UBS Group AG |
13F
|
Company |
0.9%
|
454,148
|
$5,531,523 | — | 30 Sep 2025 | |
| Schonfeld Strategic Advisors LLC |
13F
|
Company |
0.88%
|
446,372
|
$5,436,808 | — | 30 Sep 2025 | |
| DAFNA Capital Management LLC |
13F
|
Company |
0.84%
|
422,731
|
$5,148,864 | — | 30 Sep 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.78%
|
393,339
|
$4,790,869 | — | 30 Sep 2025 | |
| Thomas Andrew Crockett |
3/4/5
|
CEO, Director |
—
mixed-class rows
|
322,315
mixed-class rows
|
$4,648,801 | — | 17 Feb 2024 | |
| MARSHALL WACE, LLP |
13F
|
Company |
0.73%
|
370,773
|
$4,516,013 | — | 30 Sep 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.72%
|
364,409
|
$4,438,501 | — | 30 Sep 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.69%
|
350,723
|
$4,271,807 | — | 30 Sep 2025 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
0.64%
|
325,435
|
$3,963,798 | — | 30 Sep 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.64%
|
321,967
|
$3,921,558 | — | 30 Sep 2025 | |
| Jefferies Financial Group Inc. |
13F
|
Company |
0.57%
|
286,875
|
$3,494,138 | — | 30 Sep 2025 | |
| CITIGROUP INC |
13F
|
Company |
0.55%
|
280,656
|
$3,418,390 | — | 30 Sep 2025 | |
| Skandinaviska Enskilda Banken AB (publ) |
13F
|
Company |
0.4%
|
200,991
|
$2,449,075 | — | 30 Sep 2025 | |
| F/m Investments LLC |
13F
|
Company |
0.39%
|
199,204
|
$2,426,305 | — | 30 Sep 2025 | |
| PANAGORA ASSET MANAGEMENT INC |
13F
|
Company |
0.39%
|
197,335
|
$2,403,540 | — | 30 Sep 2025 | |
| Hennion & Walsh Asset Management, Inc. |
13F
|
Company |
0.35%
|
176,583
|
$2,150,781 | — | 30 Sep 2025 | |
| NAN FUNG TRINITY (HK) Ltd |
13F
|
Company |
0.31%
|
154,522
|
$1,882,078 | — | 30 Sep 2025 | |
| RAYMOND JAMES FINANCIAL INC |
13F
|
Company |
0.3%
|
149,306
|
$1,818,547 | — | 30 Sep 2025 | |
| SummitTX Capital, L.P. |
13F
|
Company |
0.28%
|
143,561
|
$1,748,573 | — | 30 Sep 2025 | |
| Caption Management, LLC |
13F
|
Company |
0.28%
|
141,422
|
$1,722,520 | — | 30 Sep 2025 | |
| Susquehanna Portfolio Strategies, LLC |
13F
|
Company |
0.25%
|
128,011
|
$1,559,174 | — | 30 Sep 2025 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
0.25%
|
126,052
|
$1,535,314 | — | 30 Sep 2025 | |
| Blue Owl Capital Holdings LP |
13F
|
Company |
0.25%
|
125,000
|
$1,522,500 | — | 30 Sep 2025 | |
| BOOTHBAY FUND MANAGEMENT, LLC |
13F
|
Company |
0.21%
|
107,283
|
$1,306,707 | — | 30 Sep 2025 |
Institutional Holders of KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (KALV) as of Q4 2025
As of 31 Dec 2025,
KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (KALV) was held by
161 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
66,955,502 shares.
The largest 10 holders included
VR ADVISER, LLC, Frazier Life Sciences Management, L.P., SUVRETTA CAPITAL MANAGEMENT, LLC, TANG CAPITAL MANAGEMENT LLC, BlackRock, Inc., MILLENNIUM MANAGEMENT LLC, Capital World Investors, VANGUARD GROUP INC, SILVERARC CAPITAL MANAGEMENT, LLC, and Point72 Asset Management, L.P..
This page lists
161
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
143
Q4 2025 holders
161
Holder diff
18
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 Value $ | Q4 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.